ALS player Amylyx bags $190M as it sets sail on Nasdaq amid choppy waters
ALS drug developer Amylyx got off its IPO on Friday, raising $190 million after pricing its stock at the midrange of the offering and bumping up the offering by 1.2 million shares.
Coming out at $19 a share, the biotech $AMLX is in a small group of drug developers that is testing some very choppy waters on Nasdaq at the beginning of 2022. Last year’s offerings are generally underwater on offering price as investors grew increasingly disenchanted with a sector that has grown significantly in recent years — with a stint in the red-hot zone in 2020.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.